5-amino-1mq
5-Amino-1MQ, explained.
5-Amino-1MQ is a small-molecule NNMT inhibitor that is studied in metabolic research and sold in the research-chemical market. This is a neutral overview of what it is, how it is thought to work, and its regulatory status.
Educational only — not medical advice. Consult a qualified licensed provider.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme NNMT — not actually a peptide, though it is sold alongside them. In preclinical obese-mouse studies it has been investigated in relation to fat-cell size and glucose tolerance; the proposed mechanism is sparing NAD+ and methyl reserves. There are no human trials, and it is not FDA-approved.
What 5-Amino-1MQ is
5-Amino-1MQ is the everyday name for 5-amino-1-methylquinolinium, a small molecule that blocks an enzyme called nicotinamide N-methyltransferase, or NNMT. Worth clearing up first: despite living next to peptides on research-chemical shelves, it is chemically not a peptide at all — it is a quinoline-derived cationic compound, usually supplied as the iodide salt. It came out of academic and patent work on NNMT inhibitors, where scientists were studying the enzyme's role in obesity and metabolic dysfunction. Importantly, 5-Amino-1MQ is not an approved drug or a recognized dietary ingredient; it circulates as a research chemical, so anything sold under its name today is unapproved.
How 5-Amino-1MQ is thought to work
The mechanism is biochemically specific, but so far it has only been characterized in preclinical models. NNMT, the enzyme 5-Amino-1MQ blocks, consumes two cellular resources: nicotinamide (a building block cells use to make NAD+) and S-adenosylmethionine, the body's main methyl donor. Because it draws on both pools, NNMT is sometimes described as a 'methyl sink.' The research rationale for inhibiting it is twofold. First, with NNMT activity reduced, more nicotinamide remains available to regenerate NAD+ — which in theory relates to sirtuin activity and mitochondrial energy metabolism. Second, in diet-induced obese mice, reduced NNMT activity was associated with smaller fat cells and altered metabolic markers. The catch worth repeating: the NAD+, sirtuin, and anti-obesity observations are rodent- and mechanism-level findings, not confirmed in people. NNMT is expressed across many tissues, so what chronic inhibition does in a human body is genuinely unknown.
Areas of research interest
- Adipose biology — preclinical mouse studies reporting reduced fat-cell size without diet change
- Metabolic markers and glucose tolerance, studied in obese-mouse models
- NAD+ metabolism and longevity theories — the mechanistic rationale tied to sparing NAD+ precursors and sirtuin activity
- Energy metabolism, discussed anecdotally with no controlled human data
- NNMT inhibition as a mechanistically distinct approach from GLP-1 drugs — enzyme inhibition rather than hormone mimicry
Safety & legal status
Human safety data for 5-Amino-1MQ is essentially absent, and good tolerability in mice does not establish that it is safe for people — especially since NNMT is widely expressed and the long-term, off-target, and systemic effects of inhibiting it in humans are unknown. Anecdotal user reports mention nausea, headache, sleep changes, and jitteriness, none of it systematically documented. As a research chemical, its identity and purity are not guaranteed, so what is actually in a product can vary. None of this is medical advice — consult a qualified licensed provider about your own situation. On the legal side, 5-Amino-1MQ is not FDA-approved for any use and is not a recognized dietary ingredient; it is sold research-only, status varies by country, and it may be banned in tested sport.
5-Amino-1MQ vs GLP-1 drugs
| 5-Amino-1MQ | GLP-1 / GIP drugs | |
|---|---|---|
| What it is | Small-molecule NNMT inhibitor (not a peptide) | Peptide hormone-receptor agonists (e.g. semaglutide, tirzepatide) |
| Mechanism | Blocks the NNMT enzyme to spare NAD+ and methyl reserves | Mimic gut/metabolic hormones to curb appetite and aid glucose control |
| Human evidence | None — mouse and cell data only | Large FDA-approved human weight-loss trials |
| Approval status | Not FDA-approved; research-only | FDA-approved prescription medications |
How PepEasy helps
Learn it
Get clear, cited, evidence-graded answers about 5-Amino-1MQ — what it actually is, how NNMT inhibition works, what the mouse studies showed, and where the human evidence simply doesn't exist yet.
Understand the evidence
See the regulatory status and the state of the research laid out plainly, so you can have an informed conversation with a qualified licensed provider.
Frequently asked
What are 5-Amino-1MQ's side effects?+
Human safety data is essentially absent — that's the main concern, since NNMT is widely expressed and long-term effects of inhibiting it in people are unknown. Anecdotal reports mention nausea, headache, sleep changes, and jitteriness, none systematically documented. As a research chemical, purity also varies.
What does the research on 5-Amino-1MQ show?+
Research interest centers on adipose biology and metabolic markers: in obese mice, reduced NNMT activity was associated with smaller fat cells and altered glucose tolerance without diet changes, and the mechanism theoretically spares NAD+. These are preclinical, rodent-only findings — there are no human trials.
Is 5-Amino-1MQ a steroid or a peptide?+
Neither. It is a small-molecule quinolinium compound that inhibits the NNMT enzyme. It is often sold alongside peptides and grouped with them in stores, but chemically it is not a peptide, and it is not an anabolic steroid.
Is 5-Amino-1MQ FDA approved?+
No. As of 2026 it is not FDA-approved for any use and is not a recognized dietary ingredient. It is sold as a research chemical, and marketing it as a supplement or for weight loss isn't FDA-sanctioned. Status varies by country, and it may be banned in tested sport.
Everything peptides, made easy.
Join PepEasy and get the tools, the knowledge, and the care — in one place.
Explore more